TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. Diagnosis of chronic obstructive pulmonary disease~2. Relatively stable airway obstruction with a post-bronchodilator 30% \</= Forced Expiratory Volume in 1 second (FEV1)\<80% of predicted normal and a post-bronchodilator FEV1/(Forced Vital Capacity)FVC \<70%~3. Male or female patients, 40 years of age or older~4. Smoking history of more than 10 pack years~5. Ability to perform technically acceptable pulmonary function tests and maintain records~6. Ability to inhale medication in a competent manner from the RESPIMAT Inhaler, Accuhaler and from a metered dose inhaler (MDI)~Exclusion criteria:~1. Significant disease other than COPD~2. COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or iv) or hospitalization in the last 3 months.~3. Clinically relevant abnormal lab values~4. History of asthma~5. Diagnosis of thyrotoxicosis~6. Diagnosis of paroxysmal tachycardia~7. History of myocardial infarction~8. Unstable or life-threatening cardiac arrhythmia~9. Hospitalization for heart failure within the past year~10. Known active tuberculosis~11. malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years~12. History of life-threatening pulmonary obstruction~13. History of cystic fibrosis~14. Clinically evident bronchiectasis~15. History of significant alcohol or drug abuse~16. History of thoracotomy with pulmonary resection~17. oral or patch ß-adrenergics~18. Oral corticosteroid medication within 6 weeks prior to Visit 1~19. Regular use daytime oxygen therapy for more than one hour per day~20. Pulmonary rehabilitation program in the six weeks prior to the screening visit~21. Investigational drug within one month or six half lives (whichever is greater) prior to screening visit~22. Known hypersensitivity to ß-adrenergic drugs, BAC, EDTA~23. Pregnant or nursing women

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T+O FDC dosage 1 (Type: EXPERIMENTAL): Low dose
- T+O FDC dosage 2 (Type: EXPERIMENTAL): High dose
- ICS/LABA FDC Dosage 1 (Type: ACTIVE_COMPARATOR): Low dose
- ICS/LABA FDC Dosage 2 (Type: ACTIVE_COMPARATOR): High dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetic neuropathy~Exclusion Criteria:~* Subject has previously participated in this trial or subject has previously been assigned to treatment in a trial of the drug under investigation in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects selected for this study are those who would have been prescribed Champix tablets by the physician according to the subject's condition in usual clinical practice.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Healthy smokers (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. men and women 30-80 years of age inclusive~2. type 2 diabetes mellitus diagnosed by a physician within 3 years prior to patient enrollment~3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization~4. HbA1C ≤ 8.5% on no oral hypoglycemic agents or HbA1C ≤ 7.5% on 1 agent or on half-maximal doses of 2 agents~5. body mass index ≥ 23 kg/m2~6. a negative pregnancy test and an agreement to use a reliable method of birth control for the duration of the trial in all females with childbearing potential~7. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG)~8. ability and willingness to self-inject insulin~9. provision of informed consent.~Exclusion Criteria:~1. current use of insulin therapy~2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance~3. renal dysfunction as evidenced by serum creatinine (Cr) ≥ 124 μmol/l~4. history of lactic acidosis or diabetic ketoacidosis~5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper limit of normal at the time of enrollment~6. history of inflammatory bowel disease, colonic ulcers, recent or significant bowel surgery, or predisposition to bowel obstruction~7. cardiovascular disease including any of:~   * systolic blood pressure \>180 mmHg or diastolic blood pressure \>105 mmHg~  * peripheral vascular disease~  * left bundle branch block or third degree AV block~  * tachyarrhythmias or bradyarrhythmias with uncontrolled ventricular rate~  * stenotic valvular heart disease~  * cardiomyopathy~  * history of heart failure~  * history of aortic dissection~  * documented history of angina or coronary artery disease~  * history of stroke or transient ischemic attack~8. pulmonary disease with dependence on oxygen~9. history of any disease requiring intermittent or continuous systemic glucocorticoid treatment~10. history of any major illness with a life expectancy of \<3 years~11. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity~12. any history of excessive alcohol intake, acute or chronic~13. known hypersensitivity to metformin, acarbose, or insulin glargine.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (short) (Type: EXPERIMENTAL): None
- Group 2 (long) (Type: EXPERIMENTAL): None
- Standard care (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 to 80 years of age, and gender not limited。~2. Within 48 hours of stroke onset of ischemic stroke (diagnosis standard by the Chinese medical association of the fourth national conference on cerebrovascular disease);~3. The first onset, or always not obvious legacy of stroke sequela (mRS acuities were before the onset of 1);~4. The degree of nerve function defect score (NIHSS) score 4 to 24 points, body movement component (NIHSS score paragraphs 5 and 6) total score 2 points or higher;~5. Understand and voluntarily signed informed consent.~Exclusion Criteria:~1. Head imaging studies have confirmed that, encephalitis, brain tumor, brain abscess and cause similar symptoms of disease, or confirm with hemorrhagic cerebral infarction, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc.~2. The serious disturbance of consciousness (Ia NIHSS score 2 points or higher);~3. With hemorrhagic disease or have a bleeding tendency, or have a lower limb venous thrombosis;~4. Serious abnormal liver and kidney function, liver function laboratory indexes of ALT \> 3 ULN, renal laboratory ULN Cr \> 1.5);~5. A history of mental illness or dementia patients;~6. Severe organ or other systemic disease, accompanied by any organ or system of malignant tumor, or ongoing anti-tumor treatment, the estimated lifetime \< 3 months;~7. Significant drug or alcohol abuse;~8. Allergic constitution, as well as to two or more drugs or food allergies;This medicine ingredients allergy or known;~9. Have pregnancy (check blood HCG positive screening tests, namely HCG \> 5 miu/mL), during the test preparation is pregnancy or lactation in women;~10. In the past three months in other clinical trials;~11. Researchers do not determine poor adherence, or any other suitable for patients to participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ginkgo diterpene lactone meglumine injection (Type: ACTIVE_COMPARATOR): ginkgo diterpene lactone meglumine injection
- Ginkgo diterpene lactone meglumine injection simulation (Type: PLACEBO_COMPARATOR): Ginkgo diterpene lactone meglumine injection simulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and non-pregnant women ≥18 years of age~* Patient is diagnosed with ESRD and must be on hemodialysis 3 times per week for at least 3 months prior to Screening Phase~* Patient is currently being treated with pharmaceutical vitamin D for the treatment of secondary hyperparathyroidism~* Serum iPTH value ≤500 pg/mL at first screening visit~* Total serum calcium (corrected for albumin) ≤10.5 mg/dL at first screening visit~* Serum phosphorus ≤7.0 mg/dL at first screening visit~Exclusion Criteria:~* Currently taking any of the following: drugs affecting vitamin D metabolism, digitalis, glucocorticoids, cyclosporine or other immunosuppressants, aluminum-based phosphate binders~* A daily intake \>4000 IU vitamin D (D3 + D2)~* Any investigational drug use within 10 half-lives of the drug (or within the previous 30 days if the half-life of the drug is unknown)~* History of any of the following: ventricular dysrhythmias, severe congestive heart failure, angina pectoris, myocardial infarction, coronary angioplasty, coronary artery bypass grafting, multiple myeloma, calciphylaxis, active malignancy, end-stage liver disease, active infections, clinically significant renal/urinary tract stones, sarcoidosis, tuberculosis, parathyroidectomy~* Major surgery within the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DP001 (Type: EXPERIMENTAL): DP001 softgel capsules, 440 ng taken orally three times weekly after dialysis for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo softgel capsules, taken orally three times weekly after dialysis for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rural Options At Discharge Model of Active Planning

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 and 75 years of age~* Admitted to St. Patrick regional referral hospital for treatment~* Discharged home to one of four rural counties in Montana~Exclusion Criteria:~* Primary diagnosis involves psychiatric condition or substance abuse~* Inmates of state prison~* Admitted under ongoing criminal investigation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard hospital discharge services (Type: NO_INTERVENTION): Patients received standard discharge planning; the baseline and return to baseline groups were combined to form a single standard discharge group
- Enhanced rural discharge and transition (Type: EXPERIMENTAL): Enhanced rural discharge and transition involved conducting a functional needs assessment before discharge. Identified needs were shared with a Local Community Transition Coordinator (LCTC). Needs include such patient centered issues as housing, transportation, emotional support, support for completing daily chores, and assistance in securing local follow-up appointments. Once a patient returned home, the LCTC conduct a review of discharge orders to insure a patient can meet those recommendations. Then the LCTC worked with the patient to develop and implement a transition plan that linked the patient to local resources he or she can use to address needs. The LCTC also provided direct supports. This plan was implemented over the course of the first 30 days after discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent before any assessment~* Patients with type 1 or type 2 diabetes mellitus and HbA1c of ≤10% at screening~* Medication for the management of diabetes stable within 3 months prior to randomization and is expected to remain stable during the course of the study~Exclusion Criteria:~* Active proliferative diabetic retinopathy in the study eye~* Active intraocular or periocular infection or active intraocular inflammation in study eye~* Uncontrolled glaucoma in the study eye defined as intraocular pressure (IOP) \> 25 millimeters mercury (mmHg)~* Previous treatment with anti-VEGF drugs or investigational drugs in the study eye~* Stroke or myocardial infarction during the 6-month period prior to baseline~* Uncontrolled blood pressure defined as a systolic value ≥160 mmHg or diastolic value ≥100 mmHg~Other protocol-specified inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brolucizumab 3 mg (Type: EXPERIMENTAL): Brolucizumab 3 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP).
- Brolucizumab 6 mg (Type: EXPERIMENTAL): Brolucizumab 6 mg/0.05 mL, 5 loading doses, with subsequent doses per protocol-specified maintenance schedule.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP).
- Aflibercept 2 mg (Type: ACTIVE_COMPARATOR): Aflibercept 2 mg/0.05 mL, as labeled, 5 loading doses, with subsequent doses every 8 weeks.~To fulfil the double-masking requirement, each investigational site had masked and unmasked staff. The investigator who performed the injection was unmasked to the treatments as were any other site personnel who had been delegated responsibility for working with the Investigational Product (IP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent~* Chronic plaque psoriasis for at least 6 months prior to Screening~* PASI (Psoriasis Area and Severity Index) \>=12 and BSA (body surface area) \>=10% and IGA (Investigator's Global Assessment) score 3 or greater on a 5-point scale~* Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy~* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug~* Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication~Exclusion Criteria:~* Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced psoriasis~* Subject has any severe, progressive and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastrointestinal or neurological disease~* Subject has any significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol~* Subject taking prohibited psoriatic medications~* Subject receiving any live vaccines within 8 weeks prior to the Baseline and subjects receiving Bacillus Calmette-Guerin (BCG) vaccination within 1 year prior to study drug administration~* Subject has previously received treatment with any anti-interleukin-17 (anti-IL-17) therapy or has been exposed to more than 1 biological response modifier (limited to anti-tumor necrosis factor (TNF) or IL-12/23) for psoriatic arthritis or psoriasis prior to the Baseline~* Subject has any current sign or symptom that may indicate an active infection (except for common cold)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Bimekizumab dosing regimen 1 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 2 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 3 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 4 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 5 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized in ICU~* Receiving Continuous hemodialysis~* Prescribed ertapenem~* Informed consent granted~Exclusion Criteria:~* \< 18 years of age~* Allergy to ertapenem or other carbapenem antibiotic~* Severe, life-threatening reaction to penicillin or cephalosporins~* Patients experiencing or with history of CNS disorders (eg: seizure, stroke)~* Patients experiencing CNS infection~* Inability to complete 24 hours of CVVHD~* Concurrent use of other extracorporeal therapies such as extracorporeal membrane oxygenation, plasmapheresis or intermittent hemodialysis~* Inability to obtain informed consent~* Pregnant and/or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ertapenem (Type: EXPERIMENTAL): subjects will receive ertapenem while receiving CVVHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with a diagnosis of vascular dementia according to the NINDS-AIREN International Workshop criteria or with a diagnosis of mixed dementia (possible Alzheimer's disease with cerebrovascular disease) according to the NINCDS-ADRDA criteria~* mild-to-moderate dementia (score of 10 - 25 on the Mini Mental Status Exam (MMSE) and ADAS-cog score of at least 12)~* having the opportunity to perform activities of daily living (such as dressing, bathing, etc), including patients living independently in residential homes for the elderly~* had onset of disease between ages 40 - 90~* have a consistent informant to accompany them on scheduled visits~Exclusion Criteria:~* Neurogenerative disorders such as Parkinson's disease~* cognitive impairment resulting from conditions such as acute cerebral trauma, cerebral damage due to a lack of oxygen, vitamin deficiency, infections such as meningitis or AIDS, significant endocrine or metabolic disease, mental retardation, or a brain tumor~* having significant psychiatric disease, active peptic ulcer, clinically significant liver, kidney or lung disorders, or heart disease~* history of epilepsy, convulsions, drug abuse or alcohol abuse~* females of child bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete